The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA interference medicines for the common liver condition.
The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA interference medicines for the common liver condition.
